Breaking Finance News

MEI Pharma Inc (NASDAQ:MEIP) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has downgraded MEI Pharma Inc (NASDAQ:MEIP) to Hold in a statement released on 9/22/2016.

On Monday April 18, 2016, Wedbush released a statement on MEI Pharma Inc (NASDAQ:MEIP) dropped the target price from $3.00 to $2.00 that suggested an upside of 0.29%.

Having a price of $1.73, MEI Pharma Inc (NASDAQ:MEIP) traded -1.14% lower on the day. The last stock close price is up 16.01% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the date range. MEI Pharma Inc has recorded a 50-day average of $1.86 and a two hundred day average of $1.49. Volume of trade was down over the average, with 376,065 shares of MEIP changing hands under the typical 517,508

Performance Chart


With a total market value of $0, MEI Pharma Inc has with a one year low of $0.87 and a one year high of $2.28 .

A total of 1 equity analyst has released a ratings update on the stock. 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $7.00.

General Company Details For MEI Pharma Inc (NASDAQ:MEIP)

MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *